Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leptin in Severe Insulin Resistance
NCT00027456Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Nov 2001
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metreleptin in Rabson-Mendenhall syndrome (RMS), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoints: Plasma glucose concentrations at 4 months and Glycated Hemoglobin at 4 months. Started Nov 2001; status: completed.
02
Drugs
metreleptin
03
Conditions
Rabson-Mendenhall syndrome (RMS)
Beyond the preview
Go deeper on NCT00027456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027456.